

Datasheet for ABIN1111850
Neuregulin 4 Protein (NRG4)**3** Publications[Go to Product page](#)

Overview

Quantity:	50 µg
Target:	Neuregulin 4 (NRG4)
Origin:	Human
Host:	Please inquire
Protein Type:	Recombinant
Application:	Biochemical Assay (BCA)

Product Details

Purification:	>96%, as determined by SDS-PAGE and HPLC
Endotoxin Level:	Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg)
Biological Activity Comment:	The ED(50) was determined by the phosphorylation of ErbB2 and ErbB4 receptors in CHO cells, and was found to be <3ng/ml, corresponding to a specific activity of 3x 10 ⁵ Units/mg.

Target Details

Target:	Neuregulin 4 (NRG4)
Alternative Name:	Neuregulin-4 (NRG4 Products)
Background:	Neuregulins (NDF, heregulin, GGF ARIA, or SMDF) are EGF- like growth and differentiation factors that signal through tyrosine kinase receptors of the ErbB family. The ErbB2 and ErbB4 receptors cooperate in transmission of neuregulin-1 signals in the heart, whereas ErbB2 and ErbB3 cooperate in neural crest cells.
Molecular Weight:	Recombinant human Neuregulin-4 EGF domain is a disulfide-linked monomeric protein

Target Details

consisting of 62 amino acid residue subunits, and migrates as an approximately 7 kDa protein under non-reducing and reducing conditions in SDS-PAGE.

NCBI Accession: [Q8WWG1](#)

Pathways: [RTK Signaling](#), [Fc-epsilon Receptor Signaling Pathway](#), [EGFR Signaling Pathway](#), [Neurotrophin Signaling Pathway](#)

Application Details

Restrictions: For Research Use only

Handling

Storage: -20 °C

Storage Comment: The lyophilized protein is stable for at least 2 years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

Publications

Product cited in: Park, Tait, Kawasaki, Rowley, Mackay: "Closer association of IA-2 humoral autoreactivity with HLA DR3/4 than DQB1*0201/*0302 in Korean T1D patients." in: **Annals of the New York Academy of Sciences**, Vol. 1037, pp. 104-9, (2005) ([PubMed](#)).

Iwama, Ikezaki, Kikuoka, Kim, Matsuoka, Yanagawa, Sato, Hoshi, Sakamaki, Sugihara: "Association of HLA-DR, -DQ genotype and CTLA-4 gene polymorphism with Graves' disease in Japanese children." in: **Hormone research**, Vol. 63, Issue 2, pp. 55-60, (2005) ([PubMed](#)).

Arnold, Pei, Spriewald, Wassmuth: "Anti-HLA class II antibodies in kidney retransplant patients." in: **Tissue antigens**, Vol. 65, Issue 4, pp. 370-8, (2005) ([PubMed](#)).

Spriewald, Witzke, Wassmuth, Wenzel, Arnold, Philipp, Kalden: "Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis." in: **Annals of the rheumatic diseases**, Vol. 64, Issue 3, pp. 457-61, (2005) ([PubMed](#)).

Quintero, Pizarro, Rodrigo, Piqué, Lanas, Ponce, Miño, Gisbert, Jurado, Herrero, Jiménez, Torrado, Ponte, Díaz-de-Rojas, Salido: "Association of Helicobacter pylori-related distal gastric cancer with the HLA class II gene DQB10602 and cagA strains in a southern European population." in: **Helicobacter**, Vol. 10, Issue 1, pp. 12-21, (2005) ([PubMed](#)).